HELXFranklin Genomic Advancements ETF
Seeks capital appreciation.
By Franklin Templeton Investments · Launched 2020
Annual Cost
0.50%
#2,667 of 5,861 · average
Fund Size
$28M
#4,218 of 5,861 · small
Return (1Y)Goal
+38.7%
Track Record
6 years
#2,014 of 5,861 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$13,868+38.7%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Active selection
Sector
Health careFocus
Biotech & Genomics
What it actually holds
By weightConcentration
Top 10 holdings = 45.2% of fundmoderately concentrated
Guardant Health Inc
6.8%
NATERA INC
6.6%
Krystal Biotech Inc
5.3%
United Therapeutics Corporation
4.6%
Insmed Inc
4.5%
Bridgebio Pharma Inc
4.2%
Ligand Pharmaceuticals Incorporated
3.5%
AstraZeneca PLC
3.4%
Adaptive Biotechnologies Corp
3.1%
Vertex Pharmaceuticals Incorporated
3.0%
Asset allocation
Stocks
98.7%
Cash
1.3%
By sector
Healthcare
96.7%
Basic Materials
2.3%
Technology
1.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
22.0%High
Year-on-year price swings
Max drawdown
-58.7%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.28Below average
Sortino (3Y)
0.40Moderate downside risk
Listing
- Exchange
- Cboe BZX
Full fund details
- Objective
- Seeks capital appreciation.
- Strategy
- Invests at least 80% of net assets in equity securities of companies relevant to genomic advancements, predominantly in health care industries. Focuses on companies expected to benefit from technological and scientific developments in genomics, both domestically and internationally, including emerging markets.
- Inception date
- February 25, 2020
- Fund family
- Franklin Templeton Investments
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at HELX. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04